At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Metformin 850 mg orally once daily for 1 month, then twice daily (1700 mg total daily) for 3 monthsAI-extracted
Key inclusion· 1
- ✓Metabolic syndrome defined as ≥3 of 5 alterations: abdominal obesity (waist >39.8 in men, >34.4 in women), elevated triglycerides (>150 mg/dL), low HDL (<40 mg/dL men, <50 mg/dL women), elevated BP (>130/85) or on BP treatment, or elevated fasting glucose (>100 mg/dL)
Key exclusion· 12
- ✕Diabetes treated with medication
- ✕Uncontrolled hypertension (BP >160/100 mmHg)
- ✕Clinical congestive heart failure
- ✕Moderate-to-severe anemia (hematocrit <32%)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)
In Brief
A Phase 2 clinical trial evaluating Metformin and Placebo for Obesity and 3 related conditions. Completed, enrolled 77 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Hypertension, Hypercholesterolemia, Hyperglycemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedMar 2005
Primary CompletionMay 2008
TodayJul 2026
First PostedMar 4, 2005
Enrollment StartJan 1, 2004
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 21.3 years ago
Interventions
Metformindrug
850mg tablet once a day for one month, then twice a day for 3 months
Placebodrug
placebo tablet once a day for one month, then twice a day for 3 months